The Morrison Government is investing almost $6 million in additional funding from the Medical Research Future Fund’s (MRFF) Coronavirus Research Response to support research and development of three Australian COVID-19 vaccines.
The University of Sydney, will receive almost $3 million for a Phase 1/1b clinical trial to test the safety and effectiveness of COVIGEN, a novel DNA-based COVID-19 vaccine developed by Melbourne-based Technovalia and French-Thai company BioNet.